Home / Medical Devices / Non-Invasive Prenatal Testing Market by Products (MaterniT21 PLUS, BambniTest, informaSeq Prenatal Test, Harmony Prenatal Test, Non-invasive Fetal Trisomy (NIFTY) Test, Verifi, PrenaTest, Panorama Test, VisibiliT Test) - Growth, Share, Opportunities & Competitive Analysis, 2016 - 2022

Non-Invasive Prenatal Testing Market by Products (MaterniT21 PLUS, BambniTest, informaSeq Prenatal Test, Harmony Prenatal Test, Non-invasive Fetal Trisomy (NIFTY) Test, Verifi, PrenaTest, Panorama Test, VisibiliT Test) - Growth, Share, Opportunities & Competitive Analysis, 2016 - 2022

Published: May 2016 | Report Code: 57840-05-16

This report on non-invasive prenatal testing (NIPT) market gives an all-inclusive view of the NIPT industry based on products, regional categories. The study offers market size and forecast (USD Mn) of its segments for the period 2014-2022, with respective CAGRs (value %) for the period 2016-2022, while considering 2015 as the base year. Market dynamics such as drivers, challenges and future prospects, and major commercial events are discussed in this report for evaluation of the overall market trends.

Over the decade, the global non-invasive prenatal testing (NIPT) has shown a healthy growth. The rise in the global average of maternal age, coupled with the increasing incidence of Down syndrome in newborns, has boosted the market to a significant level. Additionally, the augmenting demand for timely and non-invasive fetal diagnosis is anticipated to propel the market in the coming years.

Over the past few years, the global non-invasive prenatal testing market has underwent phenomenal growth with several tests being introduced commercially. Rise in maternal age, and growing incidence of genetic abnormalities in newborns are the most significant drivers of this market. This report scrutinizes the major NIPT tests currently available in the market, namely, MaterniT21 PLUS, BambniTest, informaSeq Prenatal Test, Harmony Prenatal Test, Non-invasive Fetal Trisomy (NIFTY) Test. verifi, PrenaTest, Panorama Test, VisibiliT Test and others.

Based on geographical distribution, the global non-invasive prenatal testing market is categorized into following sub-markets:

North America

a.    U.S.

b.    Canada

Europe

a.    U.K.

b.    Germany

c.    Rest of Europe

Asia-Pacific

a.    Japan

b.    China

c.    Rest of Asia-Pacific

Middle East and Africa
Latin America

The market size and forecast for the period 2014-2022 along with the CAGRs for the period 2016-2022 for the mentioned segments are also presented in this study.

Along with the quantitative information sets, this report also includes market assessment tools such as attractive investment proposition, major commercial events, and fractal map analysis for competitive assessment of the global non-invasive prenatal testing market. This report concludes with company profiles section that highlights key information about the major market players engaged in development, manufacture, distribution and sale of non-invasive prenatal tests in the international markets.

Non-Invasive Prenatal Testing Market

Chapter 1 Preface
1.1 Report Description
1.2 Market Segmentation
1.3 Research Methodology

Chapter 2 Executive Summary
2.1 Non-Invasive Prenatal Testing Market, by Products, 2015 (USD Mn)
2.2 Non-Invasive Prenatal Testing Market Share, by Geography, 2015 (Value %)

Chapter 3 Non-Invasive Prenatal Testing Market: Market Dynamics and Outlook
3.1 Introduction
3.2 Major Commercial Events
3.3 Drivers
3.4 Challenges
3.5 Opportunities
3.6 Attractive Investment Proposition
3.1 Competitive Analysis: Fractal Map Investigation, by Key Market Players

Chapter 4 Global Non-Invasive Prenatal Testing Market Analysis, by Products
4.1 Preface
4.2 MaterniT21 PLUS
4.3 BambniTest
4.4 informaSeq Prenatal Test
4.5 Harmony Prenatal Test
4.6 Non-invasive Fetal Trisomy (NIFTY) Test
4.7 verifi
4.8 PrenaTest
4.9 Panorama Test
4.10 VisibiliT Test

Chapter 5 Global Non-Invasive Prenatal Testing Market, by Geography
5.1 Preface
5.2 North America
5.2.1 U.S.
5.2.2 Canada
5.3 Europe
5.3.1 U.K.
5.3.2 Germany
5.3.3 Rest of Europe
5.4 Asia-Pacific
5.4.1 Japan
5.4.2 China
5.4.3 Rest of Asia-Pacific
5.5 Middle East and Africa (MEA)
5.6 Latin America

Chapter 6 Company Profiles
6.1 Ariosa Diagnostics, Inc.
6.1.1 Business Description
6.1.2 Financial Health and Budget Allocation
6.1.3 Product Positions/Portfolio
6.1.4 News Coverage
6.2 Berry Genomics Co., Ltd.
6.2.1 Business Description
6.2.2 Financial Health and Budget Allocation
6.2.3 Product Positions/Portfolio
6.2.4 News Coverage
6.3 BGI Diagnostics
6.3.1 Business Description
6.3.2 Financial Health and Budget Allocation
6.3.3 Product Positions/Portfolio
6.3.4 News Coverage
6.4 Illumina, Inc.
6.4.1 Business Description
6.4.2 Financial Health and Budget Allocation
6.4.3 Product Positions/Portfolio
6.4.4 News Coverage
6.5 Laboratory Corporation of America Holdings (LabCorp)
6.5.1 Business Description
6.5.2 Financial Health and Budget Allocation
6.5.3 Product Positions/Portfolio
6.5.4 News Coverage
6.6 LifeCodexx AG
6.6.1 Business Description
6.6.2 Financial Health and Budget Allocation
6.6.3 Product Positions/Portfolio
6.6.4 News Coverage
6.7 Natera, Inc.
6.7.1 Business Description
6.7.2 Financial Health and Budget Allocation
6.7.3 Product Positions/Portfolio
6.7.4 News Coverage
6.8 Sequenom, Inc.
6.8.1 Business Description
6.8.2 Financial Health and Budget Allocation
6.8.3 Product Positions/Portfolio
6.8.4 News Coverage
6.9 Others
6.9.1 Business Description
6.9.2 Financial Health and Budget Allocation
6.9.3 Product Positions/Portfolio
6.9.4 News Coverage

List Of Table :

TABLE 1 Global Non-Invasive Prenatal Testing Market, by Products, 2014 – 2022 (USD Mn)
TABLE 2 Global Non-Invasive Prenatal Testing Market, by Geography, 2014 – 2022 (USD Mn)
TABLE 3 North America Non-Invasive Prenatal Testing Market, by Country, 2014 – 2022 (USD Mn)
TABLE 4 Europe Non-Invasive Prenatal Testing Market, by Country, 2014 – 2022 (USD Mn)
TABLE 5 Asia-Pacific Non-Invasive Prenatal Testing Market, by Country, 2014 – 2022 (USD Mn)

List Of Figure :

FIG. 1 Non-Invasive Prenatal Testing: Market Segmentation
FIG. 2 Non-Invasive Prenatal Testing Market, by Products, 2015 (USD Mn)
FIG. 3 Non-Invasive Prenatal Testing Market Share, by Geography, 2015 (Value %)
FIG. 4 Attractive Investment Proposition, Non-Invasive Prenatal Testing Market, 2015
FIG. 5 Competitive Analysis: Fractal Map Investigation, by Key Market Players
FIG. 6 Global MaterniT21 PLUS Market, 2014 – 2022 (USD Mn)
FIG. 7 Global BambniTest Market, 2014 – 2022 (USD Mn)
FIG. 8 Global informaSeq Prenatal Test Market, 2014 – 2022 (USD Mn)
FIG. 9 Global Harmony Prenatal Test Market, 2014 – 2022 (USD Mn)
FIG. 10 Global Non-invasive Fetal Trisomy (NIFTY) Test Market, 2014 – 2022 (USD Mn)
FIG. 11 Global verifi Market, 2014 – 2022 (USD Mn)
FIG. 12 Global PrenaTest Market, 2014 – 2022 (USD Mn)
FIG. 13 Global Panorama Test Market, 2014 – 2022 (USD Mn)
FIG. 14 Global VisibiliT Test Market, 2014 – 2022 (USD Mn)
FIG. 15 U.S. Non-Invasive Prenatal Testing Market, 2014 – 2022 (USD Mn)
FIG. 16 Canada Non-Invasive Prenatal Testing Market, 2014 – 2022 (USD Mn)
FIG. 17 U.K. Non-Invasive Prenatal Testing Market, 2014 – 2022 (USD Mn)
FIG. 18 Germany Non-Invasive Prenatal Testing Market, 2014 – 2022 (USD Mn)
FIG. 19 Rest of Europe Non-Invasive Prenatal Testing Market, 2014 – 2022 (USD Mn)
FIG. 20 Japan Non-Invasive Prenatal Testing Market, 2014 – 2022 (USD Mn)
FIG. 21 China Non-Invasive Prenatal Testing Market, 2014 – 2022 (USD Mn)
FIG. 22 Rest of Asia-Pacific Non-Invasive Prenatal Testing Market, 2014 – 2022 (USD Mn)
FIG. 23 Middle East and Africa Non-Invasive Prenatal Testing Market, 2014 - 2022 (USD Mn)
FIG. 24 Latin America Non-Invasive Prenatal Testing Market, 2014 - 2022 (USD Mn)

MaterniT21 PLUS, BambniTest, informaSeq Prenatal Test, Harmony Prenatal Test, Non-invasive Fetal Trisomy (NIFTY) Test, verifi, PrenaTest, Panorama Test, VisibiliT Test and others are the major NIPT test types studied for the purpose of this research. Among these test types, the MaterniT21 PLUS test holds the largest market share in 2015. The test exhibits the capability of diagnosing a wide range of chromosomal abnormalities such as Trisomy 13, Trisomy, 18, Trisomy 21, Trisomy 16, microdeletions such as DiGeorge syndrome, Jacobsen syndrome, 1q36 deletion syndrome, Langer-Gidion syndrome, Wolf-Hirschhorn syndrome. The test first received approval in 2011 for diagnosis of Trisomy 21. Growth in the average maternity age, rise in disposable income, and offered convenience in terms of early disease detection are the prime factors that drive the growth of this market. On the other hand, stringent government guidelines, and the ethical dilemma associated with prenatal testing may hold back the growth of this market.

Non-Invasive Prenatal Testing Market 

Based on geographical segmentation, the global non-invasive prenatal testing market is studied for:

  • North America
    • U.S.
    • Canada
  • Europe
    • U.K.
    • Germany
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • Rest of Asia-Pacific
  • Latin America
  • Middle East and Africa

Non-Invasive Prenatal Testing Market

At present, North America is the leading regional market for NIPT tests, with over 50% market revenue in 2015. United States being one of the wealthiest countries in the world, is characterized by high awareness about the repercussions of genetic abnormalities, high disposable income, as well as well-structured reimbursement policies. Additionally, Asia-Pacific is the fastest growing regional market for NIPT tests. Countries such as South Korea, Japan, China and India greatly determine the market trends in this region. In Japan, approximately 60% women have higher than 1:1,000 risk of having a child with Down’s syndrome. Moreover, the number of mothers above the age of 30 is also high in the country. Among these women, a significant section opt fall under the high risk group of maternity age of 35 and above. These women represent the potential customers for NIPT testing. As per the guidelines set by the Japan Society of Gynecology, NIPT tests would be made available to pregnant women in the mentioned age-group and such women who are found at risk of carrying a genetically abnormal fetus during earlier tests.

Choose License Type
Connect With Us
+1-800-361-8290
24/7 Research Support

Credence Webinars

Join Credence analysts to explore the latest IT Trends

view upcoming webinars

Our Clients